Clopidogrel
Product Images NDC 53808-1031

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 53808-1031). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image For 75mg (Clopidogrel 75mg)

This is a description of a medication called Clopidogrel. Each tablet contains 75mg of the medication. The medication is packaged in a bottle with a quantity of 30 tablets. The lot number for the medication from the manufacturer Accord is PO7233. The medication was packaged by DOH Central Pharmacy and their lot number is 0212201408. The expiration date for the medication is 08-12-2014. The UPC code for the medication is 316720218160.*

FDA Label Image

Figure (Clopidogrel Fig1)

FDA Label Image

Figure (Clopidogrel Fig2)

This is a graph showing the cumulative event rates of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up for individuals who received either placebo (with aspirin) or clopidogrel (with aspirin) along with other standard therapies. The event rates were significantly lower for those who received clopidogrel and aspirin compared to placebo and aspirin.*

FDA Label Image

Figure (Clopidogrel Fig3)

This appears to be a table of data regarding the efficacy of clopidogrel compared to placebo on several characteristics of patients, including age, gender, diabetes, previous heart attacks, medication usage, and other factors. The table presents various metrics, such as hazard ratios and percentages, broken down by baseline and each type of characteristic. It is possible that this data is related to a clinical trial or study, but without additional context it is difficult to determine the precise nature or purpose of the research.*

FDA Label Image

Figure (Clopidogrel Fig4)

This text presents data related to a clinical study of two treatments, Placebo and Cloplodogrel. The percentage of deaths observed in each group is indicated, along with the proportional risk reduction and the days since randomization. The result shows a slightly lower percentage of deaths in the Cloplodogrel group and a statistically significant reduction of risk compared to Placebo.*

FDA Label Image

Figure (Clopidogrel Fig5)

This text appears to be a statistical report of a clinical trial comparing the effectiveness of a placebo versus a medication called Clopidogrel. The report shows the number of participants who experienced an adverse event before their first discharge, with percentages for each group. The report also indicates that using Clopidogrel resulted in a 9% proportional risk reduction, with a p value of 0.002. The information is presented over a four-week period since randomization.*

FDA Label Image

Figure (Clopidogrel Fig6)

FDA Label Image

Figure (Clopidogrel Fig7)

FDA Label Image

Change Relative To Clopidogrel Bisulfate Administered Alone (Clopidogrel Fig8)

FDA Label Image

Chemical Structure (Clopidogrel Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.